Subscribe

Ipsen S.A. (IPN.PA)

EUR159.90 +1.50 (+0.95%)
FR PAR Healthcare Medical - Pharmaceuticals
Address 70 rue Balard 75015
Boulogne-Billancourt, FR
CEO David Loew
Website ipsen.com
IPO 2005-12-07
ISIN FR0010259150

Explore sections of this company profile

Also trades on Euronext Paris · IPN.PA (EUR) Other OTC · IPSEF (USD) Other OTC · IPSEY (USD)
Description

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a inhibitor that is in phase III clinical trial for the treatment of second line follicular lymphoma; Tovorafenib that is in phase III clinical trial to treat first line pediatric Low-Grade Gliomas and is In phase II clinical trial for the treatment of relapsed/refractory pediatric Low-Grade Gliomas; and IPN01194 and IPN01195 that is in phase I to treat solid tumors. The company is also developing products for rare disease comprising Bylvay for the treatment of progressive familial intrahepatic cholestasis; Iqirvo, a peroxisome proliferator-activated receptor agonist to treat primary biliary cholangitis; NutropinAq, a liquid formulation of recombinant human growth hormone; Increlex, a recombinant human insulin-like growth factor; Fidrisertib that is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressive; Ritivixibat that is in phase II clinical trial to treat primary sclerosing cholangitis. In addition, it develops neuroscience products, such as Dysport that is in phase III clinical trial for the treatment of chronic and episodic migraine; and IPN10200 that is in phase II to treat aesthetic and therapeutic indications. The company has a partnership with Simcere Zaiming Pharmaceutical Co., Ltd. for the development of SIM0613, a protein expressed on varies tumor types and cancer-associated fibroblasts. The company was founded in 1929 and is headquartered in Paris, France.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR159.90 +1.50 (+0.95%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
130.5K
Beta
0.32
Float Shares
33.88M
Free Float %
41.0%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.51% -2.43% -6.23% -5.15% +25.99% +31.60% +51.01% +44.33% +89.18% +174.79% +560.76%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
159.90
DCF (Unlevered) 319.52 +99.8%
DCF (Levered) 231.60 +44.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 44% Bullish
Rating 2026-05 Change
Strong Buy 2 0
Buy 5 0
Hold 7 0
Sell 0 0
Strong Sell 2 0
Quality scores
Altman Z-Score
5.08
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Pharmaceuticals: +7.8%
    +2.8% Q4'25: +16.7% (vs Q4'23)
  • ✓
    EPS growth Medical - Pharmaceuticals: +20.2%
    +28.2% ★ Q4'25: -75.5% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%
    +22.5% ★ Q4'25: +30.3% (vs Q4'23)
  • ✓
    EBIT margin Medical - Pharmaceuticals: +6.8%
    +20.3% ★ Q4'25: +26.3% (vs Q4'23)
  • ✗
    ROIC Medical - Pharmaceuticals: +6.1%
    +14.9% ★ Q4'25: +36.0% (vs Q4'23)
  • ✗
    Share dilution Medical - Pharmaceuticals: +0.0%
    +0.2% Q4'25: -1.6% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×
    0.96× ★ Q4'25: 0.57× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.33) × ERP
WACC = 93% × Ke + 7% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 319.52 Current price: 159.90
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2005
actual 		Dec 2006
actual 		Dec 2007
actual 		Dec 2008
actual 		Dec 2009
actual 		Dec 2010
actual 		Dec 2011
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
11 Rev. Ana.
10 EPS Ana. 		Dec 2027
12 Rev. Ana.
11 EPS Ana. 		Dec 2028
9 Rev. Ana.
9 EPS Ana. 		Dec 2029
4 Rev. Ana.
3 EPS Ana. 		Dec 2030
4 Rev. Ana.
3 EPS Ana.
Revenue
788.71M
est: 869.22M (-9.3%)
861.68M
est: 916.66M (-6.0%)
993.76M
est: 960.67M (+3.4%)
1.04B
est: 1.05B (-0.8%)
1.11B
est: 1.10B (+1.3%)
1.17B
est: 1.14B (+2.4%)
1.23B
est: 1.20B (+2.9%)
1.28B
est: 1.26B (+1.4%)
1.28B
est: 1.27B (+0.7%)
1.33B
est: 1.33B (+0.6%)
1.52B
est: 1.46B (+3.9%)
1.67B
est: 1.61B (+3.7%)
2.01B
est: 1.94B (+3.6%)
2.35B
est: 2.27B (+3.3%)
2.69B
est: 2.61B (+3.0%)
2.69B
est: 2.65B (+1.5%)
2.75B
est: 2.91B (-5.6%)
3.16B
est: 3.09B (+2.2%)
3.31B
est: 3.44B (-3.7%)
3.57B
est: 3.50B (+2.3%)
3.68B
est: 3.76B (-2.3%)
4.28B
3.94B – 4.61B
+13.6% YoY
4.50B
3.79B – 4.99B
+5.2% YoY
4.66B
4.65B – 4.68B
+3.7% YoY
4.80B
4.23B – 5.25B
+2.9% YoY
4.76B
4.19B – 5.21B
-0.8% YoY
EBITDA
190.41M
est: 297.27M (-35.9%)
237.76M
est: 182.97M (+29.9%)
249.05M
est: 245.23M (+1.6%)
246.78M
est: 270.28M (-8.7%)
216.64M
est: 264.95M (-18.2%)
166.37M
est: 217.53M (-23.5%)
148.00M
est: 155.21M (-4.6%)
198.19M
est: 114.61M (+72.9%)
251.80M
est: 61.62M (+308.6%)
283.20M
est: 219.20M (+29.2%)
351.60M
est: 272.55M (+29.0%)
387.00M
est: 300.51M (+28.8%)
486.90M
est: 403.59M (+20.6%)
645.00M
est: 555.46M (+16.1%)
152.70M
est: 724.21M (-78.9%)
794.40M
est: 101.16M (+685.3%)
1.06B
est: 105.61M (+902.9%)
1.13B
est: 104.84M (+978.7%)
1.14B
est: 1.18B (-2.9%)
1.16B
est: 1.19B (-2.8%)
1.10B
est: 1.29B (-14.6%)
1.47B
1.35B – 1.58B
+13.6% YoY
1.54B
1.30B – 1.71B
+5.2% YoY
1.60B
1.59B – 1.60B
+3.7% YoY
1.65B
1.45B – 1.80B
+2.9% YoY
1.63B
1.44B – 1.79B
-0.8% YoY
EBIT
161.54M
est: 206.25M (-21.7%)
187.82M
est: 170.52M (+10.1%)
217.57M
est: 196.19M (+10.9%)
195.27M
est: 225.21M (-13.3%)
171.71M
est: 191.71M (-10.4%)
126.98M
est: 179.63M (-29.3%)
75.95M
est: 135.17M (-43.8%)
127.95M
est: 79.55M (+60.8%)
226.20M
est: 127.89M (+76.9%)
249.50M
est: 194.33M (+28.4%)
313.60M
est: 248.87M (+26.0%)
348.20M
est: 264.22M (+31.8%)
400.40M
est: 370.40M (+8.1%)
504.20M
est: 469.13M (+7.5%)
-7.90M
est: 595.82M (-101.3%)
559.90M
est: -36.66M (+1,627.2%)
812.90M
est: -38.28M (+2,223.7%)
943.70M
est: -38.00M (+2,583.7%)
861.00M
est: 811.41M (+6.1%)
455.40M
est: 823.07M (-44.7%)
746.30M
est: 889.11M (-16.1%)
1.01B
930.21M – 1.09B
+13.6% YoY
1.06B
894.97M – 1.18B
+5.2% YoY
1.10B
1.10B – 1.10B
+3.7% YoY
1.13B
998.87M – 1.24B
+2.9% YoY
1.12B
990.53M – 1.23B
-0.8% YoY
Net Income
119.23M
est: 129.99M (-8.3%)
144.01M
est: 125.70M (+14.6%)
151.07M
est: 150.91M (+0.1%)
147.67M
est: 162.36M (-9.0%)
157.17M
est: 156.69M (+0.3%)
95.27M
est: 163.07M (-41.6%)
424.0K
est: 100.01M (-99.6%)
-29.49M
est: 419.8K (-7,124.8%)
152.54M
est: -29.85M (+611.0%)
153.50M
est: 157.38M (-2.5%)
189.90M
est: 172.24M (+10.3%)
225.90M
est: 205.61M (+9.9%)
272.30M
est: 274.73M (-0.9%)
389.50M
est: 321.73M (+21.1%)
-54.90M
est: 446.78M (-112.3%)
548.00M
est: -52.76M (+1,138.7%)
646.60M
est: -55.08M (+1,273.8%)
648.60M
est: 406.20M (+59.7%)
644.40M
est: 663.90M (-2.9%)
345.90M
est: 795.83M (-56.5%)
444.50M
est: 979.00M (-54.6%)
1.08B
982.11M – 1.17B
+10.0% YoY
1.12B
910.19M – 1.32B
+3.8% YoY
919.05M
840.83M – 1.41B
-17.8% YoY
1.20B
1.02B – 1.35B
+30.8% YoY
1.30B
1.10B – 1.46B
+8.2% YoY
SGA
66.79M
est: 294.82M (-77.3%)
75.22M
est: 379.01M (-80.2%)
401.48M
est: 401.39M (+0.0%)
444.30M
est: 432.86M (+2.6%)
484.61M
est: 472.95M (+2.5%)
521.06M
est: 504.62M (+3.3%)
526.62M
est: 546.85M (-3.7%)
572.57M
est: 552.68M (+3.6%)
548.50M
est: 579.37M (-5.3%)
577.10M
est: 572.87M (+0.7%)
665.90M
est: 645.52M (+3.2%)
718.80M
est: 719.64M (-0.1%)
857.60M
est: 896.89M (-4.4%)
954.10M
est: 1.01B (-5.7%)
1.02B
est: 1.09B (-6.7%)
972.20M
est: 1.06B (-8.2%)
916.20M
est: 1.11B (-17.2%)
1.04B
est: 1.10B (-5.4%)
1.13B
est: 916.45M (+23.8%)
1.17B
est: 929.62M (+26.2%)
—
est: 1.00B (-100.0%)
1.14B
1.05B – 1.23B
+13.6% YoY
1.20B
1.01B – 1.33B
+5.2% YoY
1.24B
1.24B – 1.25B
+3.7% YoY
1.28B
1.13B – 1.40B
+2.9% YoY
1.27B
1.12B – 1.39B
-0.8% YoY
EPS
1.42
est: 1.56 (-8.9%)
1.71
est: 1.72 (-0.4%)
1.80
est: 1.76 (+2.2%)
1.75
est: 1.80 (-2.6%)
1.86
est: 1.67 (+11.4%)
1.13
est: 1.58 (-28.7%)
0.01
est: 1.79 (-99.4%)
-0.35
est: 1.59 (-122.0%)
1.71
est: 1.80 (-4.9%)
1.88
est: 2.22 (-15.2%)
2.30
est: 2.82 (-18.5%)
2.74
est: 3.03 (-9.6%)
3.27
est: 4.20 (-22.2%)
4.67
est: 5.79 (-19.3%)
-0.66
est: 6.57 (-110.0%)
6.61
est: 6.87 (-3.8%)
7.64
est: 8.59 (-11.0%)
7.20
est: 9.71 (-25.9%)
7.79
est: 8.02 (-2.9%)
4.18
est: 9.68 (-56.8%)
5.32
est: 11.71 (-54.6%)
12.96
11.75 – 14.01
+10.7% YoY
13.32
10.89 – 15.86
+2.7% YoY
13.24
10.06 – 16.83
-0.5% YoY
14.38
12.16 – 16.16
+8.6% YoY
15.57
13.16 – 17.48
+8.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-28 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-27 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-26 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-25 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-22 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-21 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-20 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-19 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-18 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-15 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-14 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-13 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-12 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-11 A- 4/5 4/5 4/5 5/5 2/5 2/5 3/5
2026-05-08 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-05-07 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-05-06 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-05-05 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-05-04 A- 4/5 4/5 4/5 5/5 2/5 3/5 3/5
2026-04-30 A- 4/5 4/5 3/5 5/5 2/5 3/5 3/5
2026-04-29 A- 4/5 4/5 3/5 5/5 2/5 3/5 3/5
2026-04-28 A- 4/5 4/5 3/5 5/5 2/5 3/5 3/5
2026-04-27 A- 4/5 4/5 3/5 5/5 2/5 3/5 3/5
2026-04-24 A- 4/5 4/5 3/5 5/5 2/5 3/5 3/5
2026-04-23 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5
2026-04-22 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5
2026-04-21 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5
2026-04-20 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5
2026-04-17 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5
2026-04-16 B+ 3/5 4/5 3/5 5/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.96B
OE per share TTM
23.57
Owner's Yield
15.20%
Maintenance CapEx ratio
3.81%
Maint CapEx / Avg PPE
20.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 325 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 iShares Genomics Immunology and Healthcare ETF IDNA 3.57% 6.99M 0.47%
2 BMO Low Volatility International Equity ETF ZLI.TO 1.02% 2.05M 0.45%
3 Lazard International Dynamic Equity ETF IDEQ 0.99% 12.86M 0.40%
4 Distillate International Fundamental Stability & Value ETF DSTX 0.87% 438.4K 0.55%
5 UBS Factor MSCI EMU Quality Screened UCITS ETF EUR dis UD04.L 0.85% 977.5K 0.25%
6 VictoryShares International Free Cash Flow Growth ETF GRIN 0.83% 2.31M 1.06%
7 VictoryShares International Free Cash Flow ETF IFLO 0.80% 1.49M 1.05%
8 iShares Healthcare Innovation UCITS ETF HEAL.L 0.76% 8.63M 0.40%
9 iShares EURO STOXX Mid UCITS ETF DJMC.L 0.75% 4.78M 0.40%
10 VictoryShares International Value Momentum ETF UIVM 0.60% 1.95M 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
136.2K
Shares Outstanding
82.71M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
David Loew MD, Chief Executive Officer & Director 2M male
Aymeric Le Chatelier Executive Vice President & Chief Financial Officer 731.3K male
Dominique Bery Head of Nordics & Baltics — female
Henry Wheeler Global Vice President of Investor Relations — male
James Levine President of Fondation Ipsen — —
Mari Scheiffele Executive VP, Chief Product Officer & Head of GPPS — female
Philippe Lopes-Fernandes Executive Vice President & Chief Business Officer — male
Pierrick Lefranc Executive Vice President of Technical Operations — male
Aidan Murphy Executive Vice President and Head of Technical Operations — —
Regis Mulot Executive Vice President & Chief Human Resources Officer — male
Caroline Sitbon Executive Vice President & General Counsel — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Pharmaceuticals